These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 39170618)
1. Traversing the bench to bedside journey for iNKT cell therapies. O'Neal J; Mavers M; Jayasinghe RG; DiPersio JF Front Immunol; 2024; 15():1436968. PubMed ID: 39170618 [TBL] [Abstract][Full Text] [Related]
2. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review. Tang C; Zhang Y Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830 [TBL] [Abstract][Full Text] [Related]
3. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295 [TBL] [Abstract][Full Text] [Related]
4. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment. Wang Y; Li YR Curr Pharm Biotechnol; 2024; 25(15):2001-2011. PubMed ID: 38310449 [TBL] [Abstract][Full Text] [Related]
5. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510 [TBL] [Abstract][Full Text] [Related]
6. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253 [TBL] [Abstract][Full Text] [Related]
8. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597 [TBL] [Abstract][Full Text] [Related]
14. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM Front Immunol; 2020; 11():1804. PubMed ID: 32973756 [TBL] [Abstract][Full Text] [Related]
15. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach. Sinkovics JG Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Rafei H; Daher M; Rezvani K Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984 [TBL] [Abstract][Full Text] [Related]
17. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. Schneidawind D; Pierini A; Alvarez M; Pan Y; Baker J; Buechele C; Luong RH; Meyer EH; Negrin RS Blood; 2014 Nov; 124(22):3320-8. PubMed ID: 25293774 [TBL] [Abstract][Full Text] [Related]
18. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Trujillo-Ocampo A; Cho HW; Herrmann AC; Ruiz-Vazquez W; Thornton AB; He H; Li D; Qazilbash MA; Ma Q; Porcelli SA; Shpall EJ; Molldrem J; Im JS Cytotherapy; 2018 Aug; 20(8):1089-1101. PubMed ID: 30076070 [TBL] [Abstract][Full Text] [Related]
19. Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy. Takami M; Motohashi S Front Immunol; 2024; 15():1457771. PubMed ID: 39224603 [TBL] [Abstract][Full Text] [Related]
20. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells. Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I Cells; 2020 Jul; 9(8):. PubMed ID: 32707982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]